Patients diagnosed with THRLBCL have been treated with chemotherapy regimens similar to the regimens used to treat DLBCL. These earlier used chemotherapy regimens (e.g. the CHOP regimen consisting of three chemotherapy drugs (cyclophosphamide, hydroxydoxorubicin, and oncovin) plus a glucocorticoid, either prednisone or prednisolone) achieve complete response rates of 48% to 85%, 3-year overall survival rates of 50% to 64%, and 5 year overall survival rates of 46% to 58%. The addition of immunotherapy drug, rituximab, to the CHOP regimen appears to have improved these results: in one study, patients receiving the R-CHOP regimen had a three-year overall survival rate of 75%. Since treatment of the variant form of nodular lymphocyte predominant Hodgkin lymphoma using different and less aggressive drug regimens achieves better results than the regimens used to treat THRLBCL, it is clinically important to distinguish the two diseases.
T cell/histiocyte-rich large B-cell lymphoma
Diffuse large B-cell lymphoma associated with chronic inflammation
Germinal center B-cell like diffuse large B-cell lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Fibrin-associated diffuse large B-cell lymphoma
Pediatric-type follicular lymphoma
Nodal marginal zone B cell lymphoma
Marginal zone B-cell lymphoma